Sucralfate


Generic Medicine Info
Administration
Should be taken on an empty stomach. Take on an empty stomach 1 hr before or 2 hr after meals.
Special Precautions
Patient with diabetes mellitus; conditions that may impair swallowing (e.g. recent or long-term intubation, dysphagia, tracheostomy, history of aspiration), or other conditions that may alter gag/cough reflex or reduce oropharyngeal coordination or motility. Patients who are seriously ill, particularly those with delayed gastric emptying and concurrent enteral feedings. Treatment guidelines may vary among individual products (refer to product-specific recommendations). Renal impairment (e.g. chronic renal failure or those receiving dialysis). Elderly. Pregnancy and lactation. Monitoring Parameters Monitor blood glucose levels in diabetic patients taking the oral susp. Monitor Al phosphate, Ca and alkaline phosphatase periodically, and signs of Al toxicity in patients with renal impairment.
Adverse Reactions
Significant: Increased risk of Al accumulation and toxicity such as Al osteodystrophy, osteomalacia and encephalopathy (in patients renal with impairment); bezoar formation and intestinal obstruction (in seriously ill patients); hyperglycaemia (susp); aspiration accompanied with respiration complications (tab). Ear and labyrinth disorders: Vertigo. Gastrointestinal disorders: Constipation, diarrhoea, flatulence, gastric discomfort, dry mouth, dyspepsia, nausea, vomiting. Immune system disorders: Hypersensitivity reactions (e.g. dyspnoea, urticaria, anaphylaxis). Musculoskeletal and connective tissue disorders: Back pain. Nervous system disorders: Dizziness, drowsiness, headache. Psychiatric disorders: Insomnia. Skin and subcutaneous tissue disorders: Pruritus, rash.
Drug Interactions
May decrease the absorption of digoxin, quinidine, fluoroquinolones, tetracycline, ketoconazole, sulpiride, levothyroxine, phenytoin, ranitidine, cimetidine, warfarin and theophylline; consider dosing interval of at least 2 hours between sucralfate and other concomitant non-antacid drugs. May increase the total body burden of Al when concomitantly used with other preparation that contains Al (e.g. Al-containing antacids). If antacids are concurrently needed, a dosing interval of 30 minutes between sucralfate and antacids is recommended.
CIMS Class
Antacids, Antireflux Agents & Antiulcerants
ATC Classification
A02BX02 - sucralfate ; Belongs to the class of other drugs used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Disclaimer: This information is independently developed by CIMS based on sucralfate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in